ALXO Stock Analysis: Buy, Sell, or Hold?
ALXO - ALX Oncology Holdings Inc. Common Stock
$2.04
0.25 (13.97%)
▲
5d:
+33.33%
30d:
+4.08%
90d:
+0.0%
BUY
MODERATE Confidence
Analysis Updated: Jun 26, 2026 12:00 AM ET
Earnings: Aug 11, 2026
Get Alerted When ALXO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: ALXO shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: ALXO shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: ALXO is currently trading at $2.04, which is considered extended relative to its 30-day fair value range of $1.53 to $1.94.
Technical Outlook: Technically, ALXO is in a downtrend. Immediate support is located at $1.37, while resistance sits at $2.13. The stock is showing strong short-term momentum, up 14.0% recently.
Market Sentiment: ALXO has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $4.60 (+125.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ALXO is in a downtrend. Immediate support is located at $1.37, while resistance sits at $2.13. The stock is showing strong short-term momentum, up 14.0% recently.
Market Sentiment: ALXO has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $4.60 (+125.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$1.53 -
$1.94
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BEARISH: Price extended above range (+5.2% above its trading range)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+14.0%)
- BULLISH: Trading 125.5% below Wall St target ($4.60)
Trading Range Analysis
30-Day Trading Range
$1.53 -
$1.94
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$1.37
Resistance Level
$2.13
Current Trend
Downtrend
Technical data as of
Jun 26, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.79
Wall Street Target
$4.60
(+125.5%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: June 27, 2026 2:53 AM ET
Data refreshes hourly during market hours. Next update: 3:53 AM
Data refreshes hourly during market hours. Next update: 3:53 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ALXO showing a specific setup today?
Insider Activity (6 Months)
1
Buys
3
Sells
Net
INSIDERS SELLING
Recent Transactions
Jason Lettmann
SELL
12311 shares
2026-03-19
Shelly Pinto
SELL
903 shares
2026-03-19
Corey S Goodman
BUY
3184713 shares
2026-02-02
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 51 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$31 | 62 BUY |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$122 | 56 HOLD |
|
DYN
Dyne Therapeutics Inc |
STRONG BUY
14 analysts |
$38 | 56 HOLD |
|
CNTA
Centessa Pharmaceuticals… |
STRONG BUY
11 analysts |
$44 | 61 BUY |
Advanced ALXO Option Strategies
Professional options setups generated by AI based on today's ALXO price and gamma walls.
